
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 30, 2022, titled "Zydus receives final approval from the USFDA for Triazolam Tablets".
Filed with NSE ·

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 30, 2022, titled "Zydus receives final approval from the USFDA for Triazolam Tablets".
6ix hasn’t read this filing yet.
Zydus Lifesciences Limited on 6ix
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences